Octagon Capital Advisors as of Dec. 31, 2021
Portfolio Holdings for Octagon Capital Advisors
Octagon Capital Advisors holds 28 positions in its portfolio as reported in the December 2021 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
---|---|---|---|---|---|
Apellis Pharmaceuticals (APLS) | 18.6 | $96M | 2.0M | 47.28 | |
Arcus Biosciences Incorporated (RCUS) | 16.5 | $85M | 2.1M | 40.47 | |
I Mab Sponsored Ads (IMAB) | 9.7 | $50M | 1.0M | 47.39 | |
4d Molecular Therapeutics In (FDMT) | 6.6 | $34M | 1.6M | 21.94 | |
Bridgebio Pharma (BBIO) | 5.7 | $30M | 1.8M | 16.68 | |
Celldex Therapeutics Com New (CLDX) | 5.7 | $29M | 761k | 38.64 | |
Iteos Therapeutics (ITOS) | 4.1 | $21M | 451k | 46.56 | |
Keros Therapeutics (KROS) | 3.9 | $20M | 340k | 58.51 | |
Stoke Therapeutics (STOK) | 3.7 | $19M | 784k | 23.99 | |
Vera Therapeutics Cl A (VERA) | 3.5 | $18M | 671k | 26.72 | |
Gossamer Bio (GOSS) | 3.3 | $17M | 1.5M | 11.31 | |
Arvinas Ord (ARVN) | 2.9 | $15M | 179k | 82.14 | |
Century Therapeutics (IPSC) | 2.2 | $11M | 703k | 15.86 | |
Avidity Biosciences Ord (RNA) | 2.1 | $11M | 447k | 23.77 | |
Chinook Therapeutics | 1.6 | $8.2M | 500k | 16.31 | |
Prometheus Biosciences | 1.5 | $7.9M | 200k | 39.54 | |
Dyne Therapeutics (DYN) | 1.4 | $6.9M | 584k | 11.89 | |
Cytek Biosciences (CTKB) | 1.3 | $6.5M | 400k | 16.32 | |
Cardiff Oncology (CRDF) | 1.1 | $5.9M | 983k | 6.01 | |
Immunovant (IMVT) | 0.9 | $4.9M | 573k | 8.52 | |
Helix Acquisition Corp Com Cl A | 0.8 | $4.0M | 400k | 9.89 | |
Monte Rosa Therapeutics (GLUE) | 0.6 | $3.1M | 150k | 20.42 | |
Ambrx Biopharma Sponsored Ads | 0.6 | $3.0M | 337k | 9.03 | |
Jiya Acquisition Corp Com Cl A | 0.6 | $2.9M | 300k | 9.77 | |
Olema Pharmaceuticals (OLMA) | 0.4 | $2.2M | 231k | 9.36 | |
Omega Therapeutics Common Stock (OMGA) | 0.4 | $2.0M | 177k | 11.33 | |
Connect Biopharma Hldgs Ads (CNTB) | 0.3 | $1.4M | 280k | 5.15 | |
Compass Therapeutics (CMPX) | 0.1 | $761k | 240k | 3.17 |